Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
17 pending office actions • 12 art units • 15 examiners • 0 of 17 (0%) have an AI response strategy ready • 21 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (18%) |
| §103 only | 5 (29%) |
| §112 only | 2 (12%) |
| Double-patenting + other | 1 (6%) |
| Multi-statute (no §101) | 5 (29%) |
| No statute on record | 1 (6%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIGIL, TORIANA NICHOLE | 2 | 52.4% | +25.2% |
| ALFANO, ALAN | 2 | — | — |
| ORWIG, KEVIN S | 1 | 25.4% | +40.2% |
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
| HAMA, JOANNE | 1 | 25.6% | +38.2% |
| DUTT, ADITI | 1 | 47.0% | +48.5% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
| SCHMIDT, IZABELA MARIA | 1 | 65.3% | +42.5% |
| SCOTLAND, REBECCA LYNN | 1 | 0.0% | +0.0% |
| HUYNH, PHUONG N | 1 | 65.8% | +53.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039498 | FORMULATIONS | SCOTLAND, REBECCA LYNN | 5d |
| 18248651 | BINDING MOLECULES THAT MULTIMERISE CD45 | OUSPENSKI, ILIA I | 33d |
| 18760979 | HUMANISED ANTIBODIES | ORWIG, KEVIN S | — |
| 18684711 | ANTI-HLA-G ANTIBODIES | HAMA, JOANNE | — |
| 18422323 | ANTIBODY MOLECULES WHICH BIND IL-17A AND IL-17F | DUTT, ADITI | — |
| 18277594 | ANTIBODIES | ALFANO, ALAN | — |
| 18251006 | USE OF ANTI-TREM1 NEUTRALIZING ANTIBODIES FOR THE TREATMENT OF MOTOR NEURON NEURODEGENERATIVE DISORDERS | HUYNH, PHUONG N | — |
| 18028736 | Nucleic Acid Constructs, Viral Vectors and Viral Particles | MCLEOD, AFRICA MHAIRIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18632964 | Imaging Agents | DONOHUE, SEAN R | 81d overdue |
| 18703675 | FORMULATIONS | VIGIL, TORIANA NICHOLE | 7d |
| 18760979 | HUMANISED ANTIBODIES | ORWIG, KEVIN S | — |
| 18703661 | FORMULATIONS | VIGIL, TORIANA NICHOLE | — |
| 18684711 | ANTI-HLA-G ANTIBODIES | HAMA, JOANNE | — |
| 18422323 | ANTIBODY MOLECULES WHICH BIND IL-17A AND IL-17F | DUTT, ADITI | — |
| 18267925 | AMORPHOUS SOLID DISPERSIONS | CHANDRAKUMAR, NIZAL S | — |
| 18265156 | Octahydroisoquinolinyl Derivatives | SCHMIDT, IZABELA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1641 | 3 |
| 1612 | 2 |
| 3991 | 1 |
| 1618 | 1 |
| 1625 | 1 |
| 1621 | 1 |
| 1615 | 1 |
| 1644 | 1 |
| 1635 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18760979 | HUMANISED ANTIBODIES | ORWIG, KEVIN S | 3991 | Other | Non-Final OA | — | Pending | Jul 01, 2024 |
| 18703661 | FORMULATIONS | VIGIL, TORIANA NICHOLE | 1612 | §103 | Final Rejection | — | Pending | Apr 22, 2024 |
| 18703675 | FORMULATIONS | VIGIL, TORIANA NICHOLE | 1612 | §103 | Final Rejection | 7d | Pending | Apr 22, 2024 |
| 18632964 | Imaging Agents | DONOHUE, SEAN R | 1618 | §103 | Final Rejection | 81d overdue | Pending | Apr 11, 2024 |
| 18684711 | ANTI-HLA-G ANTIBODIES | HAMA, JOANNE | — | §101§112 | Non-Final OA | — | Pending | Feb 19, 2024 |
| 18422323 | ANTIBODY MOLECULES WHICH BIND IL-17A AND IL-17F | DUTT, ADITI | — | §101DP | Non-Final OA | — | Pending | Jan 25, 2024 |
| 18277594 | ANTIBODIES | ALFANO, ALAN | 1641 | §102§112 | Non-Final OA | — | Pending | Aug 17, 2023 |
| 18267925 | AMORPHOUS SOLID DISPERSIONS | CHANDRAKUMAR, NIZAL S | 1625 | §112Other | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18265156 | Octahydroisoquinolinyl Derivatives | SCHMIDT, IZABELA MARIA | 1621 | §103DP | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18039498 | FORMULATIONS | SCOTLAND, REBECCA LYNN | 1615 | §103 | Non-Final OA | 5d | Pending | May 31, 2023 |
| 18251006 | USE OF ANTI-TREM1 NEUTRALIZING ANTIBODIES FOR THE TREATMENT OF MOTOR NEURON NEURODEGENERATIVE DISORDERS | HUYNH, PHUONG N | 1641 | §102§103§112Other | Final Rejection | — | Pending | Apr 28, 2023 |
| 18248651 | BINDING MOLECULES THAT MULTIMERISE CD45 | OUSPENSKI, ILIA I | 1644 | §102§103§112 | Non-Final OA | 33d | Pending | Apr 11, 2023 |
| 18028736 | Nucleic Acid Constructs, Viral Vectors and Viral Particles | MCLEOD, AFRICA MHAIRIE | 1635 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 27, 2023 |
| 18045623 | Methods of Treatment Using Anti-IL-17A/F Antibodies | SCHWECHTER, BRANDON ROSS | 1674 | §102§103§112 | Non-Final OA | — | Pending | Oct 11, 2022 |
| 17907116 | AUTONOMOUS KNOB DOMAIN PEPTIDES | ALFANO, ALAN | 1641 | §112 | Final Rejection | 4d overdue | Pending | Sep 23, 2022 |
| 17787094 | MULTI-SPECIFIC ANTIBODIES | CHATTIN, AMY MARIE | 1643 | §102§103§112 | Non-Final OA | — | Pending | Jun 17, 2022 |
| 17286247 | METHOD FOR THE TREATMENT OF MYASTHENIA GRAVIS | HOLTZMAN, KATHERINE ANN | 1646 | §103Other | Final Rejection | 80d overdue | Pending | Apr 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial